Navigation Links
Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Date:5/8/2008

ults at the annual meeting of the

American Academy of Allergy, Asthma & Immunology (AAAAI) in

Philadelphia, PA.

-- New pre-clinical findings on the treatment of prostate cancer models

at the American Association for Cancer Research conference. The

studies explored the physiologic responses to enzymatic removal of

hyaluronic acid (HA)-based matrices surrounding tumor cells in the

tumor microenvironment of prostate tumors following systemic

administration of its pegylated rHuPH20 (PEG PH20) pre-clinical

candidate. The objectives of these studies were to determine whether

HA-dependent pericellular matrices produced in vitro and in vivo by a

hormone refractory prostate cancer cell line could be enzymatically

depleted in prostate carcinoma xenografts following intravenous (IV)

administration of the PEG PH20 enzyme. In mice, IV PEG PH20 collapsed

the protective HA-based pericellular matrices of prostate cancer cells

and selectively increased tumor vascular volume 3.5-fold.

-- Findings on the local tolerability and pharmacokinetics of

bisphosphonates combined with PH20 at the American Association for

Cancer Research conference. The objectives of the presented studies

were to investigate in animal models whether increasing the dispersion

and absorption of bisphosphonates in the skin and subcutaneous tissues

with PH20 could modify injection site reaction profiles from two

intravenous bisphosphonate formulations, zoledronic acid and

ibandronate. The pharmacokinetics of bisphosphonates in blood were

also examined and compared to intravenous infusion. The maximal

concentration of bisphosphonates that could be administered without

producing injection site reactions was increased 3-to-5 fold when

co-administered
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
2. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
3. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
8. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
9. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
10. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
11. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... ROTTERDAM, Netherlands, April 24 LyondellBasell Industries today ... voluntarily added to Lyondell Chemical Company,s reorganization filing ... to protect the European holding company against claims ... LyondellBasell Industries AF S.C.A. is a holding company ...
... Maryland have published their assembly of the domestic cow ... the genetics community. The new version of the cow ... both completeness and accuracy. The article describing their research ... Genome Biology . , The research team led ...
... (Nasdaq: KERX ) today announced the appointment of ... Executive Officer, replacing Michael S. Weiss, effective immediately. Mr. ... since September 2007. Mr. Tarnok spent the majority of ... as Finance Director -- US Manufacturing. From 2000-2007, Mr. ...
Cached Biology Technology:LyondellBasell Adds Holding Company to Chapter 11 Protection 2New cow genome sequence released 2Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... N.J., Aug. 14 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... a private placement in which it received $2.8 million ... CEO, stated, "The,proceeds of this financing will help fund ... fourth quarter of this year." At the closing, ...
... Investors Convert Debentures to Equity, JERICHO, N.Y., Aug. ... developer and supplier of consumer,biometric products, today announced that ... Series B common stock warrants that such holders,must surrender ... The Company notified holders of 375,000 series B ...
... in September issue of Nature Methods Shows Application of ... Attachment ... Expression., GENEVA, Switzerland, Aug. 21 Researchers at ... identification of novel,high-performance Genetic Elements also known as matrix ...
Cached Biology News:SyntheMed Completes $2.8 Million Equity Financing 2bioMETRX, Inc. Calls Series B Warrants 2Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines 2
Macrophage-stimulating protein receptor...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Biology Products: